What is a stock summary page? Click here for an overview.
Business Description
Bionano Genomics Inc
NAICS : 334516
SIC : 3841
ISIN : US09075F3055
Description
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.37 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -16.9 | |||||
| Beneish M-Score | 7.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -14.7 | |||||
| 3-Year EBITDA Growth Rate | 21.8 | |||||
| 3-Year EPS without NRI Growth Rate | 23.8 | |||||
| 3-Year FCF Growth Rate | 30.1 | |||||
| 3-Year Book Growth Rate | -70.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 84.18 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 44.31 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.13 | |||||
| 9-Day RSI | 30.44 | |||||
| 14-Day RSI | 23.16 | |||||
| 3-1 Month Momentum % | -63.05 | |||||
| 6-1 Month Momentum % | -81.48 | |||||
| 12-1 Month Momentum % | -90.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | |||||
| Quick Ratio | 0.76 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 209.9 | |||||
| Days Sales Outstanding | 80.54 | |||||
| Days Payable | 107.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.2 | |||||
| Shareholder Yield % | -633.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 1.24 | |||||
| Operating Margin % | -249.3 | |||||
| Net Margin % | -363.98 | |||||
| FCF Margin % | -217.83 | |||||
| ROE % | -163.05 | |||||
| ROA % | -84.12 | |||||
| ROIC % | -75.64 | |||||
| 3-Year ROIIC % | 10.03 | |||||
| ROC (Joel Greenblatt) % | -293.99 | |||||
| ROCE % | -139.29 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.02 | |||||
| PB Ratio | 0.17 | |||||
| Price-to-Tangible-Book | 0.23 | |||||
| EV-to-EBIT | -0.06 | |||||
| EV-to-EBITDA | -0.07 | |||||
| EV-to-Revenue | 0.2 | |||||
| EV-to-Forward-Revenue | 0.43 | |||||
| EV-to-FCF | -0.1 | |||||
| Price-to-GF-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -1767.15 | |||||
| FCF Yield % | -781.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bionano Genomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 572.843 | ||
| EPS (TTM) (MXN) | -9556.357 | ||
| Beta | 1.21 | ||
| 3-Year Sharpe Ratio | -2.07 | ||
| 3-Year Sortino Ratio | -1.96 | ||
| Volatility % | 88.57 | ||
| 14-Day RSI | 23.16 | ||
| 14-Day ATR (MXN) | 2.275649 | ||
| 20-Day SMA (MXN) | 65.402 | ||
| 12-1 Month Momentum % | -90.2 | ||
| 52-Week Range (MXN) | 58 - 1199.999997 | ||
| Shares Outstanding (Mil) | 3.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bionano Genomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bionano Genomics Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bionano Genomics Inc Frequently Asked Questions
What is Bionano Genomics Inc(MEX:BNGO)'s stock price today?
The current price of MEX:BNGO is MXN62.00. The 52 week high of MEX:BNGO is MXN1200.00 and 52 week low is MXN58.00.
When is next earnings date of Bionano Genomics Inc(MEX:BNGO)?
The next earnings date of Bionano Genomics Inc(MEX:BNGO) is 2025-05-08 Est..
Does Bionano Genomics Inc(MEX:BNGO) pay dividends? If so, how much?
Bionano Genomics Inc(MEX:BNGO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers